Compare AbCellera Biologics Inc (ABCL) vs Elastic NV (ESTC) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

Elastic (ESTC) trades at $58.54, up 0.86% with neutral technical signals. The company shows strong profitability metrics including 76% gross margins and 21% net income margin projected for 2026, though 2025 results showed a net loss. Recent earnings beats and positive analyst sentiment (67% buy ratings) support the stock, with a $72.80 consensus price target representing 24% upside potential.

ESTC presents a growth opportunity with improving financials and market leadership in search AI, though risks include ongoing legal investigations and competitive pressures. The stock's current valuation appears reasonable relative to growth prospects, with technical indicators suggesting consolidation near key support at $57.